5.80 USD
▼-0.14-2.36%
盘后 5.80 -0.01%
2026-09-15
市值
$2.03B
市盈率
—
EPS
-0.44
股息率
—
52 周区间
2.99 – 9.75
成交量
7.05M
Beta
1.53
目标价
13.10
52W 低 2.9952W 高 9.75
价格走势
公司简介
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company’s lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headqua...